Document Detail


Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.
MedLine Citation:
PMID:  22897904     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: No studies of the clinical symptoms before starting therapy or of the effectiveness of neuraminidase inhibitors (NAIs) have been carried out of the 2009-2010 and 2010-2011 seasons that compare A(H1N1)pdm09 or the three circulating types of influenza virus.
METHODS: The clinical symptoms and duration of fever (body temperature ≥37·5°C) after the first dose of an NAI (oseltamivir, zanamivir, laninamivir) were analyzed. PCR was carried out for 365 patients with A(H1N1)pdm09 in the 2009-2010 season and for 388 patients with one of the three types of influenza circulating in the 2010-2011 season. IC50 for the three NAIs was also analyzed in 51 patients in the 2010-2011 season.
RESULTS: The peak body temperature was significantly higher in 2010-2011 than in 2009-2010 for patients under 20 years with A(H1N1)pdm09, and in the 2010-2011 season for children 15 years or younger with A(H1N1)pdm09 than for those with other virus types. The percentage of A(H1N1)pdm09 patients with loss of appetite or fatigue was significantly higher in 2010-2011 than in the previous season. The duration of fever was not affected by the kind of NAI or by age in multiple regression analysis. The percentage of patients afebrile at 48 hours after the first dose of NAI was significantly higher for A(H1N1)pdm09 than for A(H3N2) (laninamivir) or B (oseltamivir and laninamivir).
CONCLUSION: Although the clinical symptoms of A(H1N1)pdm09 were slightly more severe in the 2010-2011 season, the effectiveness of the NAIs remained high in comparison with 2009-2010 and with other types of seasonal influenza.
Authors:
Naoki Kawai; Hideyuki Ikematsu; Takashi Kawashima; Tetsunari Maeda; Hiroshi Ukai; Nobuo Hirotsu; Norio Iwaki; Seizaburo Kashiwagi
Related Documents :
21808724 - The frequency of nonmotor symptoms among advanced parkinson patients may depend on inst...
21682824 - An analysis of factors affecting the incidence of inhibitor formation in patients with ...
6807994 - Precipitins to an aflatoxin-producing strain of aspergillus flavus in patients with mal...
1915464 - Pelvic malignancy presenting as a pelvic inflammatory process in pre and postmenopausal...
10604664 - Ulnar neuropathy as a complication of macular hole surgery.
6103154 - Are nitrite and n-nitroso compounds in gastric juice risk factors for carcinoma in the ...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2012-08-16
Journal Detail:
Title:  Influenza and other respiratory viruses     Volume:  7     ISSN:  1750-2659     ISO Abbreviation:  Influenza Other Respir Viruses     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-18     Completed Date:  2013-09-30     Revised Date:  2013-10-30    
Medline Journal Info:
Nlm Unique ID:  101304007     Medline TA:  Influenza Other Respir Viruses     Country:  England    
Other Details:
Languages:  eng     Pagination:  448-55     Citation Subset:  IM    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Affiliation:
Japan Physicians Association, Tokyo Medical Association Building 3F, Tokyo, Japan. nkawai@city.gifu.med.or.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Antiviral Agents / therapeutic use*
Child
Child, Preschool
Enzyme Inhibitors / therapeutic use*
Female
Fever / diagnosis,  drug therapy,  epidemiology,  virology
Humans
Infant
Influenza A Virus, H1N1 Subtype / drug effects*,  genetics,  isolation & purification,  physiology
Influenza A Virus, H3N2 Subtype / drug effects*,  genetics,  isolation & purification,  physiology
Influenza, Human / diagnosis,  drug therapy*,  epidemiology*,  virology
Inhibitory Concentration 50
Male
Middle Aged
Neuraminidase / antagonists & inhibitors*
Oseltamivir / therapeutic use
Seasons
Severity of Illness Index
Treatment Outcome
Young Adult
Zanamivir / therapeutic use
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Enzyme Inhibitors; 0/Oseltamivir; 139110-80-8/Zanamivir; EC 3.2.1.18/Neuraminidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Study protocol: EXERcise and cognition in sedentary adults with early-ONset dementia (EXERCISE-ON).
Next Document:  Palliative radiotherapy for patients with tracheobronchial and esophageal compression due to intrath...